Subconjunctival mydricaine injections are used in routine practice in patients with uveitis to prevent the formation of permanent posterior synechiae.1 Mydricaine No 2 (Moorfields Eye Hospital formulation) contains a combination of 6 mg procaine hydrochloride, 1 mg atropine sulphate and 0.12 ml epinephrine solution (1 in 1000). As it is normally injected subconjunctivally, this may prove difficult to administer to anxious, young patients, especially those who are needle-phobic. Belonephobia, the abnormal fear of sharply pointed objects, especially needles, affects up to 10% of the population and has implications for treatment and …